Navigation Links
Aerolef in Medical Technology

YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain

MISSISSAUGA, ON, May 02, 2007 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced top-line results from its randomized, placebo-controlled Phase IIb trial of AeroLEF(TM) in o...

YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial

- Company Announces Lead Investigator for U.S. Trial - MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced results of secondary endpoint data f...

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...
Aerolef in Biological Technology

YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

YM BIOSCIENCES ANNOUNCES FDA LIFTS CLINICAL HOLD ON AEROLEF(R) AND CLEARANCE OF A PHASE II CLINICAL TRIAL

... - Dr. Ali Raza To Lead Further Development Of aerolef As President Of aerolef Division - MISSISSAUGA, ON, June 19 /PRNewswire-...of the Phase II clinical development of AeroLEF. aerolef is being developed as a novel and effective approa...
Other Tags
(Date:4/24/2014)... Pa. (April 24, 2014) - Contact lenses coated with an ... lens-related infections, reports a study in Optometry and ... Academy of Optometry . The journal is published by ... Wolters Kluwer Health . , Studies in animals and now ... the antimicrobial peptide melimine, according to the new research by ...
(Date:4/24/2014)... before, during and after colorectal surgery cut hospital stays ... researchers who led a study of the approach at ... is easier on patients before surgery, doing away with ... prescribed. After surgery, patients are encouraged to eat and ... recoveries. , Among findings published in the May 2014 ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... the corresponding terminology, and the relevance of palliation ... publications on randomized controlled trials (RCTs). This is ... Institute for Quality and Efficiency in Health Care ... report. , Together with external experts, IQWiG analysed ... lung cancer, malignant melanoma, and pancreatic cancer. For ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
Breaking Medicine News(10 mins):Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3
(Date:4/23/2014)... in French and Spanish . ... 2014Today, the CEC released its Conservation Assessment for the ... Conservation, which identifies 29 priority conservation areas in a ... different protected areas in the states of Texas, Coahuila, ... and semi-arid habitats inhabited by rare and endangered plants ...
(Date:4/23/2014)... a unique rhythmic sound, recorded for decades in the ... minke whale ( Balaenoptera bonaerensis ). First described and ... it sounded like a duck, the bio-duck sound has ... but its source has remained a mystery, until now. ... deployed acoustic tags on two Antarctic minke whales in ...
(Date:4/23/2014)... TX (4/23/14) -- Researchers have found evidence of ... factors that increase aggressive behavior in children, especially ... not all children exposed to prenatal smoking will ... will not," said Brian Boutwell, Assistant Professor at ... and senior author on the study. "One ...
Breaking Biology News(10 mins):Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3Genetics risk, prenatal smoking may predict behavioral problems 2
Other Contents